
Olmedip5 mg+40 mg
Ibn-Sina Pharmaceuticals Ltd.
Amlodipine + Olmesartan Medoxomil is a fixed-dose combination of a dihydropyridine calcium channel blocker (amlodipine) and an angiotensin II receptor blocker (ARB, olmesartan medoxomil) and more.
Amlodipine + Olmesartan Medoxomil is a fixed-dose combination of a dihydropyridine calcium channel blocker (amlodipine) and an angiotensin II receptor blocker (ARB, olmesartan medoxomil), indicated for:
Amlodipine + Olmesartan Medoxomil is not indicated for initial therapy in patients who require blood pressure reduction of more than 20/10 mmHg without prior assessment, as recommended by treating physicians on a case-by-case basis, and is not intended as a first-line drug for hypertensive emergencies.
Amlodipine + Olmesartan Medoxomil is taken once daily, with or without food, and should be swallowed whole with water.
| Clinical Situation | Recommended Dose |
|---|---|
| Initial therapy in adults not at goal on monotherapy | 5 mg/20 mg once daily |
| Dose titration (if blood pressure not controlled after 1-2 weeks) | Increase to a maximum of 10 mg/40 mg once daily, at intervals of at least 2 weeks |
Because of a greater sensitivity to amlodipine in patients ≥75 years, initiation of Amlodipine + Olmesartan Medoxomil as a starting combination product is generally not recommended in this age group; treatment should instead be titrated using the individual components under physician guidance.
No initial dosage adjustment of Amlodipine + Olmesartan Medoxomil is required in patients with moderate to marked renal impairment, but renal function and serum potassium should be monitored periodically.
Amlodipine + Olmesartan Medoxomil is generally not recommended as initial therapy in patients with hepatic impairment; if used, doses should be adjusted cautiously and the patient monitored closely, since amlodipine clearance is reduced in hepatic impairment.
Safety and efficacy of Amlodipine + Olmesartan Medoxomil in pediatric patients have not been established; it is not recommended for use in children.
The most common adverse effect reported with Amlodipine + Olmesartan Medoxomil is:
Less common but clinically important adverse effects include:
Amlodipine + Olmesartan Medoxomil is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.